The Great Weight Loss Injection Showdown: Wegovy vs Mounjaro — Which One Is Right for You?

The Weight Loss Revolution Is Here — But Which Injection Should You Choose?

If you've been following the news lately, you'll know that weight loss injections have transformed the landscape of obesity medicine in the UK. Both Wegovy and Mounjaro are generating enormous interest — from GP surgeries to national headlines — and for good reason. These treatments represent a genuine medical breakthrough, helping people achieve meaningful, sustained weight loss that was previously out of reach for many.

But if you're weighing up your options, the question isn't simply which injection is 'better'. It's about which is right for you, your body, your health history, and your personal goals. At Happy Pharmacy, our regulated online pharmacy team is here to cut through the noise and give you the honest, evidence-based picture.

What Are Wegovy and Mounjaro?

Both are once-weekly injectable medications licensed in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA) for weight management in adults with obesity or overweight with related health conditions. They are prescription-only treatments — meaning they must always be prescribed by a qualified clinician following a proper medical assessment.

Wegovy contains semaglutide, a GLP-1 receptor agonist manufactured by Novo Nordisk. It mimics the natural hormone GLP-1, released after eating, to reduce appetite and slow gastric emptying — helping you feel fuller for longer and significantly reducing what many patients describe as 'food noise'.

Mounjaro contains tirzepatide, made by Eli Lilly, and works on two hormone pathways simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual-action mechanism means it targets appetite and blood sugar regulation through two separate routes, which may explain its impressive results in clinical trials.

Wegovy vs Mounjaro: At a Glance

The table below summarises the key differences between the two treatments to help you get a clear, personal picture before speaking to a clinician.

Sources: MHRA; NICE; SURMOUNT-5 trial (NEJM, 2025); STEP UP trial (Lancet Diabetes & Endocrinology, 2025); SELECT trial (NEJM, 2023).

How Do the Results Compare?

For a long time, Mounjaro held a clear numerical advantage in weight loss results. The landmark SURMOUNT-5 trial — the first head-to-head comparison published in the New England Journal of Medicine in 2025 — directly compared both medications at their standard maximum doses. Participants on Mounjaro 15mg lost an average of 20.2% of body weight over 72 weeks, compared with 13.7% on Wegovy 2.4mg. That's a statistically significant difference of 6.5 percentage points.

However, the picture has shifted considerably. Wegovy now has an approved higher dose of 7.2mg available in the UK, and the STEP UP trial — published in The Lancet Diabetes & Endocrinology — showed that at this maximum dose, Wegovy achieves an average weight loss of 20.7% over 72 weeks. That means at the highest approved doses, the two treatments now produce remarkably similar results.

A real-world study by Second Nature (published in JMIR Formative Research, 2025) comparing both medications within a structured behavioural support programme found that outcomes in practice were also very close — with the gap narrowing to around 5 percentage points when patients received proper lifestyle coaching alongside treatment. Both cohorts actually exceeded the clinical trial averages, highlighting the importance of support alongside medication.

Safety Profiles: What You Need to Know

Both Wegovy and Mounjaro are well-tolerated by most patients, and both carry a broadly similar side effect profile. The most common effects — particularly when starting or increasing the dose — are gastrointestinal in nature. These may include:

•       Nausea (most common, usually short-lived)

•       Constipation or diarrhoea

•       Stomach discomfort or bloating

•       Headaches, often related to changes in hydration or food intake

Rarer but more serious side effects include pancreatitis, gallstones, and severe allergic reactions. If you experience any of these, treatment should be stopped immediately and medical attention sought. Neither medication is suitable for those with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).

Clinical evidence suggests Mounjaro may be very slightly better tolerated overall, though this difference is modest. Wegovy has a longer track record in the UK market, having received MHRA approval earlier than Mounjaro.

Crucially, Wegovy currently holds an additional safety distinction: it is the only weight loss medication approved for cardiovascular risk reduction. The SELECT trial (NEJM, 2023) demonstrated that semaglutide 2.4mg reduced the risk of major adverse cardiovascular events — including heart attack and stroke — by 20% compared with placebo. This makes Wegovy a particularly strong option for patients with existing cardiovascular risk factors. Mounjaro's equivalent cardiovascular outcomes trial (SURPASS-CVOT) is ongoing, with results anticipated soon.

NHS Access, NICE Guidelines, and What to Expect

NICE guidelines recognise obesity as a chronic condition and recommend that treatment with weight loss medications should continue for at least 12 months, with potential continuation if safe and effective. Both Wegovy and Mounjaro have received NICE approval.

Wegovy has been available via NHS specialist weight management services for longer, with access typically requiring a BMI of 35 or above alongside at least one weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnoea. Mounjaro received NHS approval for weight management in December 2024, but NHS access remains very limited in practice — most patients currently access it through private prescription only.

It's worth noting that NHS waiting lists for tier 3 specialist weight management services currently range from 6 to 24 months, depending on your region. Private online pharmacies like Happy Pharmacy offer a regulated, clinician-assessed route to access these treatments with considerably less waiting.

So — Which One Is Right for You?

There is no single 'best' answer, and any reputable healthcare provider should be honest about that. The right treatment is deeply personal. Here is a straightforward framework to help you think it through:

Ultimately, the most important thing is to have this conversation with a qualified clinician — someone who can review your full medical history, current health status, and personal weight loss goals, and recommend the most appropriate treatment for you as an individual.

How Happy Pharmacy Can Support You

At Happy Pharmacy, we believe that safe, effective weight loss treatment should be accessible to everyone — not just those who can wait years on an NHS list. As a GPhC-registered online pharmacy, we offer a regulated, personal service where every patient receives a thorough clinical consultation before any prescription is issued.

Our online consultation process is simple, confidential, and conducted by qualified clinicians who understand the latest evidence on weight loss injections. Whether you're considering starting Wegovy or Mounjaro for the first time, or looking to switch treatments, we're here to provide honest, personal support every step of the way. Find out more at here.

Blog medically reviewed by : Palvinder Deol, GPhC Registered Pharmacist, 25 February 2026

1. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). New England Journal of Medicine. 

2. Once-Weekly Semaglutide 7.2mg for Obesity (STEP UP trial). The Lancet. 

3. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial). New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

4. NICE. Obesity: identification, assessment and management). National Institute for Health and Care Excellence. 

5. MHRA. Tirzepatide (Mounjaro): UK regulatory approval for weight management.  

6. NHS. Obesity.  

7. Second Nature. Wegovy vs Mounjaro real-world comparison study.